Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 0.00% | 204.73 | 0.0% | $1981.02m | |
| NVAX | Novavax, Inc. | 0.00% | 110.82 | 78.2% | $792.93m | |
| BIIB | Biogen, Inc. | 0.00% | 239.30 | 1.8% | $522.63m | |
| AMGN | Amgen, Inc. | 0.00% | 235.36 | 1.4% | $522.04m | |
| BNTX | BioNTech SE | 0.00% | 196.00 | 0.0% | $501.82m | |
| GILD | Gilead Sciences, Inc. | 0.00% | 71.77 | 1.0% | $472.12m | |
| ILMN | Illumina, Inc. | 0.00% | 405.14 | 3.3% | $406.87m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.00% | 615.24 | 2.7% | $388.21m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.00% | 234.06 | 1.9% | $331.63m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 0.00% | 3.17 | 0.7% | $221.59m | |
| EXAS | EXACT Sciences Corp. | 0.00% | 78.43 | 17.9% | $151.61m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 0.00% | 148.50 | 8.2% | $151.18m | |
| ARNA | Arena Pharmaceuticals, Inc. | 0.00% | 92.65 | 13.7% | $144.29m | |
| INCY | Incyte Corp. | 0.00% | 74.88 | 2.4% | $128.10m | |
| BBIO | BridgeBio Pharma, Inc. | 0.00% | 12.75 | 0.0% | $115.66m |
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.